It is not fully understood how antigenic drift of the haemagglutinin of type A influenza virus in man occurs in the presence of the expected polyclonal antibody response to the five antigenic sites, A to E. Here we show that 12 % (11/92) of sera from mice which had mounted a secondary immune response to inactivated influenza virus were able to select escape mutants. No escape mutant was selected with serum from nonimmunized mice (0/65). Selection required only a single passage, and escape mutants were identified by their reaction with monoclonal antibodies (MAbs); all but one had altered reactivity at site A. Most of the site A escape mutants (7/10) were conventional in character and did not react in haemagglutination-inhibition (HI) or neutralization assays with the identifying MAb. The HA genes of three of these were part sequenced and had a predicted single amino acid substitution (Gly-144 ~ Glu) in site A. The other escape mutants (3/10) had a small (2-fold) reduction in HI and neutralization to the site A MAb, but no amino acid substitution in site A. The final mutant was a conventional site B escape mutant. To model antisera which selected escape mutants, we constructed 'pseudo-immune sera' using mixtures of two neutralizing MAbs in which the first MAb was held at a constant high concentration (1000 HIU/ml). Escape mutants could be selected to the first MAb when the titre of the second MAb was reduced to a low but still inhibiting concentration (1 to 3 HIU/ml). Mixtures of three MAbs also selected escape mutants with similar facility provided that the second and third MAbs were reduced to a similar low concentration. Thus it is possible that the ability of an antiserum to select escape mutants is due to the neutralizing antibody response being biased to an epitope/cross-reacting epitopes within a single antigenic site. However, when escape mutants were reacted in HI assay with their selecting antiserum, the maximum difference from the titre with wt virus was 75 %. The findings of this study may be relevant to the understanding of antigenic drift in type A human influenza virus, and to immune-driven antigenic variation in other virus infections.
Introduction
There are 14 subtypes of type A influenza virus (HI to HI4), which are defined by the antigenicity of their haemagglutinin protein. All these viruses naturally infect birds, mainly sea birds and freshwater fowl (Webster et al., 1992) , but so far only three (H1, H2 and H3) have infected man. On first appearing in man a new subtype causes pandemics with high morbidity and mortality. These have occurred in 1918 , 1957 and 1968 . In 1918 an H1 virus caused 20 million deaths worldwide in young adults (Kilbourne, 1987) , but in subsequent pandemics mortality has largely affected the over-65 year olds and especially those with predisposing clinical conditions such as heart and respiratory disease. However, despite the devastation of new pandemics, a considerably greater total of morbidity and mortality occurs in the intervening epidemic years (Kilbourne, 1987) . This is due largely to 'antigenic drift' of the viral haemagglutinin (HA) whereby progressive mutations render impotent the immunity acquired to earlier infection. Four or more amino acid changes occurring in at least two of the five antigenic sites of the HA are generally seen in drift variants of epidemiological importance (Wilson & Cox, 1990) .
Ideas on the mechanism by which antigenic drift occurs in vivo are based on the study of the HA sequence of natural variants and of anti-HA neutralizing antibody escape mutants. When any type A influenza virus is mixed with a neutralizing monoclonal antibody (MAb) and inoculated into a suitable host system, a population of virus is selected which is no longer neutralized by the selecting MAb. This is a universal phenomenon with viruses. Usually (but not always) the selecting antibody no longer binds to its cognate antigenic site (reviewed by Dimmock, 1993) and usually (but not always) there is a 0001-2748 © 1994 SGM
R. Lambkin and others
single nucleotide change in that site which results in a single amino acid substitution (Laver et al., 1979a; Webster & Laver, 1980; Wiley et al., 1981; Wilson & Cox, 1990) . Individual sites mutate independently of each other and changes occur at a frequency from around 10 5 but this can be much lower (Portner et al., 1980; Lubeck et al., 1980) . No escape mutants arose when selection was attempted with mixtures of two or more MAbs directed to non-overlapping epitopes (Laver et al., 1979b; Yewdell et al., 1979; Webster & Laver, 1980) , presumably because the chance of a double mutant arising (< 10 10) is vanishingly small.
The HA protein has up to five discrete antigenic sites (A to E) although, in some strains, site E is masked by a carbohydrate moiety (Skehel et al., 1984) . It is generally held that infection or immunization with virus stimulates a polyclonal antibody response -a mixture of antibodies to different antigenic sites which are heterogeneous with regard to affinity, isotype and other properties. If this is so, it is difficult to explain how antibody-escape mutants can arise since mixtures of just two MAbs to nonoverlapping epitopes do not elicit escape mutants (see above). Evidence that antigenic drift in influenza virus is driven by antibody first came from the use of antiserum, but this had been carefully depleted of avid antibody by prior adsorption with virus and escape mutants arose only after nine passages in the presence of antibody (Laver & Webster, 1968) . Others have analysed human sera and shown that the majority does indeed contain antibodies to more than one of the antigenic sites on the HA (Wang et al., 1986) , although the response may be narrower in children (Haaheim, 1980) and some adults (Natali et al., 1981) .
In this study we have investigated whether or not unmodified immune mouse serum is able to select escape mutants, and found that 12% of the antisera tested selected escape mutants with a similar reactivity to MAbs. To model this situation we made 'pseudoimmune sera' by mixing together two or three MAbs directed against different antigenic sites, and found that in certain proportions these mixtures were also able to select escape mutants as if there was only a single MAb present. The latter offers an explanation of the constitution of immune sera that readily gave rise to escape mutants.
Methods
Viruses. A/fowl plague virus/Rostock/34 (A/FPV/R: H7NI) and A/fowl plague virus/Dutch/27 (A/FPV/D: H7NT) were plaquepurified and grown in the allantoic cavity of 10-day-old embryonated chicken's eggs for 20 h at 36 °C. Purified virus was prepared by sedimentation from allantoic fluid and centrifugation through a 10 to 40% sucrose velocity gradient. A/FPV/R and A/FPV/D have an unrelated neuraminidase and a closely related HA. The HAs have 93'8% homology at the amino acid level (Munk et al., 1992) and are indistinguishable by haemagglutination-inhibition (HI) with immune serum and a number of MAbs. However, there is a one-way cross reaction at site D, presumably as a result of A/FPV/R having amino acid His-210 and A/FPV/D having Gin-210: MAbs to site D of the A/FPV/R HA failed to react with A/FPV/D, but antiserum to A/FPV/D reacts in HI with site D of A/FPV/R. Site E of neither strain is masked by carbohydrate (Roberts et al., 1993) . Infectivity was measured by plaque assay in monolayers of MDCK cells under an agar overlay medium. For biological cloning, on two successive occasions a plug of agar over a plaque was removed and virus contained therein grown up in embryonated eggs or MDCK cells.
Monoclonal antibodies. Mouse MAbs HC2 (site A), HC10 (site B) and HC61 (site D) (Sugrue et al., 1990) Taylor et al., 1987) . Serum was obtained from heart blood on day 28. All animal experiments followed the guidelines laid down by the U.K. Coordinating Committee for Cancer Research.
Selection of neutralizing antibody escape mutants by incubation with immune serum. Two protocols were used: in Protocol 1, 2001~I containing 106 p.f.u. A/FPV/R and 100 HIU of immune serum were incubated together for 1 h at 25 °C before inoculation into 10-day-old embryonated chicken's eggs. Protocol 2 was more rigorous and proved to be the method of choice: virus and antiserum were incubated at 25 °C as before and then at 4 °C overnight and the amount of antiserum was increased to 300 HIU/200 txl where possible. Eggs were infected with virus antiserum mixtures and allautoic fluid harvested after 48 h incubation at 35 °C. Escape mutants to MAbs were selected by incubating virus 106 p.f.u, and 500 HIU in 1 ml in the usual way.
Identification of escape mutants. Virus which grew in the presence of mouse antiserum was screened as a possible escape mutant by its reaction in HI with a panel of MAbs. However, we showed experimentally with an artificial mixture of wt and escape mutant that the escape mutant could be identified in this way only when the mixture contained 50 % or more of escape mutant (data not shown). Escape mutants which might be a minor component of a virus population were identified by screening in a neutralization assay with MAbs. Virus was mixed with each MAb in turn, incubated at 25 °C for 1 h and then plaque assayed. When only wt was present, no plaques were seen at the dilutions tested (see Table 3 ). Escape mutants were then plaquepurified, retested with MAbs and stocks prepared in embryonated eggs.
Escape mutants which represented only 5 % of a population could be isolated in this way.
Sequencing of escape mutants. Virion RNA was extracted with phenol-chloroform from stocks of plaque-purified escape mutants. The region between nucleotides 34 and 1090 was reverse transcribed using appropriate primers (Porter et al., 1979) and AMV reverse transcriptase (Life Sciences Inc.) and amplified by the polymerase chain reaction using AmpliTaq (Perkin Elmer Cetus). The sequence between nucleotides 300 and 500 was determined using the USB ATaq cycle sequencing kit (Cambridge BioScience) with a 32P-endlabelled primer. Each sequence was determined at least three times.
Results

Immunization of mice
In Experiment 1 BALB/c and C3H/He mice were immunized with 100, 10 or 1 HIU of BPL-inactivated A/FPV/D, or mock-immunized with diluent. While there was a specific HI response to A/FPV/R which was roughly proportional to the dose of immunogen, certain individuals, even amongst those given the highest dose, responded with an HI titre which was indistinguishable from background (data not shown). However, all sera were used, as described below, in an attempt to select escape mutants. In Experiment 2 the immunizations were repeated with two more strains of mice (DBA/1 and C57BL/6) and extending the lower range of immunogen (Table 1) . Overall doses of l0 or more HAU/mouse gave a reliable HI antibody response.
Selection of escape mutants with immune sera
Sera from mice immunized in Experiment 1 were examined for their ability to select escape mutants by Protocol 1 (see Methods). Sera from Experiment 2 were examined initially by Protocol 1 (not shown) but, as this yielded no escape mutants, the remaining antisera were tested by the more rigorous Protocol 2. Fig. 1 summarizes these findings. Virus grew in the presence of all antisera tested by Protocol 1 (Experiments 1 and 2) but 22 % of sera tested by Protocol 2 (Experiment 2) were completely neutralizing. Viruses which grew in the presence of antisera were tested (without prior plaque-purification) by HI against a panel of five MAbs (HC2, HC10, HC61, I2 and I7). This showed that 12 % of breakthrough virus in Experiment 1 and 9% of breakthrough virus in Experiment 2 (a total of 6/56 or 11% of antisera tested) were escape mutants by the definition that their HI titres differed significantly from that with wt virus. However, the escape mutants fell into two categories (see below). With the caveat that there were only a small number of escape mutants and only small numbers (6 to 16) of mice in each group immunized, the following conclusions can be made: mutants were selected only from mice immunized with 10 or 100 HAU; no mutant was selected from 33 mock-immunized mice or 57 immunized mice which gave an insignificant HI antibody response (total of 0/90); escape mutants were obtained from 3/22 BALB/c, 2/20 C3H/He and 1/6 DBA/1 mice, but none from C57BL/6 mice (total of 0/8). However, the 11% of escape mutants identified is a minimum figure since the remaining virus-positive samples (obtained with 80 % or 45/56 of antisera tested) could be (a) mutants which reacted normally with our identifying MAbs, (b) predominantly wt virus which concealed a minor proportion of escape mutants-this proved to be so for three antisera (see below), or (c) breakthrough wt virus. All six antiserum-escape mutants had reduced HI reactivity with MAb HC2 (site A) but reacted normally with MAb HC10 (site B) and HC61 (site D) ( Table 2 ). The six escape mutants fell into two categories: those which had no detectable HI activity with MAb HC2 (SJll8, F2.4 and F29.2: Group I) and those which had reduced, but nevertheless reproducible, activity with HC2 (SJ93, SJ106 and SJ4: Group II). The same reactivity pattern was maintained with neutralization by HC2. Escape mutants in Group I failed to bind HC2 in 
Identification of the mutation in escape mutants
T h e m u t a t i o n p u t a t i v e l y r e s p o n s i b l e for the altered reactivity o f the a n t i s e r u m escape m u t a n t s to M A b H C 2 was d e t e r m i n e d by s e q u e n c i n g the r e g i o n o f the H A gene c o n t a i n i n g site A. T h o s e G r o u p I m u t a n t s with greatly r e d u c e d H I activity w i t h H C 2 h a d a single n u c l e o t i d e c h a n g e w i t h i n site A w h i c h gave a p r e et al., 1991) . T h e G r o u p II escape m u t a n t s (with low reactivity to H C 2 ) h a d n o m u t a t i o n w i t h i n site A o r b e t w e e n n u c l e o t i d e s 300 a n d 500 o f the H A gene. E s c a p e m u t a n t S J l l 8 also h a d a silent m u t a t i o n (A-480 ~ C) w h i c h was n o t p r e s e n t in the M A b H C 2 escape m u t a n t R L 3 , suggesting t h a t it is a de novo isolate a n d n o t a l a b o r a t o r y c o n t a m i n a n t .
Selection of escape mutants where there is less mutant present than w t virus
A n escape m u t a n t c a n n o t be d e t e c t e d by H I assay in artificial m i x t u r e s o f wt a n d escape m u t a n t w h e n m o r e t h a n 50 % wt virus is p r e s e n t ( d a t a n o t shown). T h u s we , and 105 and terminally bled 7 days after each injection (#2, #3 and #4 respectively). Selection of escape mutants with immune sera was made using Protocol 2. The mean HI titre for each group of six animals is shown.
used neutralization to determine if any of the viruses from Experiment 2 (Fig. 1) , which grew in the presence of antiserum and were not immediately identifiable as escape mutants by HI, contained a minority population of escape mutant. To do this we added enough M A b to neutralize the wt virus present and then plaque-assayed for escape mutants. Control wt virus was completely neutralized by each of the MAbs HC2 (site A), HC10 (site B) or HC61 (site D), whereas M A b escape mutants were not neutralized by their cognate MAb but were completely neutralized by the MAbs specific for the other two antigenic sites (Table 3a) . (Table 2) and thus validated this new approach. Plaques were picked and grown up in embryonated eggs. All proved to be group I mutants with > 99 % reduction in H I and neutralization. Thus this method resulted in the isolation of three new escape mutants, and showed that it is possible to detect escape mutants in a mixture in which they represent only 5% of the total virus present. Breakthrough virus from Experiment 1 has not been tested.
Selection of escape mutants by antiserum simulated by multiple immunizations
The ability of antisera to select escape mutants after mice have been immunized on multiple occasions was addressed here. BALB/c mice were given two, three or four intravenous injections of 10 or 100 H I U of inactivated A / F P V / D at 35 day intervals. The H I antibody titre increased with each additional immunization and sera, obtained 7 days after each boost, were used with Protocol 2 in an attempt to isolate escape mutants. Fig. 2 shows that two such escape mutants were found using antiserum from mice given three injections of virus. These were both site A mutants which failed to react with MAb HC2, with a > 32-fold reduction in HI titre and were hence classified as Group I escape mutants. Thus three immunizations did not abrogate the ability of sera to select escape mutants. Nothing can be concluded about the failure of antisera from mice immunized four times to select escape mutants because of the small numbers used.
Reactivity of antiserum escape mutants with their selecting antiserum by HI
The ability of all but one of the Group I escape mutants to react by HI with its selecting antiserum was reduced by 50 to 75% compared with wt virus (Table 4 ),
indicating that up to 75% of the antibodies in an antiserum are directed to a single epitope. We have no information about the specificity of antibodies which are active against the escape mutant, and it is possible that they are directed to many different epitopes and/or antigenic sites, so that even when there is only a small drop in HI titre (see below) this may still represent the major single antibody specificity present in the antiserum. The remaining Group I mutant and the Group II mutants did not differ detectably from wt. However, this is not to say they are identical as the HI test is not sensitive enough to register a difference of less than 50 %. In a control reaction, all antiserum escape mutants gave an identical H I titre with a site D MAb (HC61). In another control each antiserum used here gave the same reduction in HI titre to a conventional MAb HC2-selected escape mutant as it did with the escape mutant that it had selected, suggesting that there was no intrinsic difference between antiserum-selected and MAb-selected viruses. The same was true of the antiserum which selected escape mutant V32.1, the only site B mutant, and a conventional site B escape mutant (data not shown).
Selection of escape mutants using a 'pseudo-immune serum' made with mixtures of MAbs to different antigenic sites
The possibility that genuinely polyclonal antisera can select escape mutants was tested by making 'pseudoimmune sera' with mixtures of two MAbs specific for different antigenic sites of A/FPV/R (site A, site B, site D). The procedure was to serially dilute the second MAb while keeping the first constant at 1000 HIU/ml (Table  5 ). In the example shown, escape mutants arose when MAb #2 was diluted to ~< 2 HIU/ml. Table 6(a) shows that all pairwise combinations of the three MAbs used in this study gave rise to mutants of A/FPV/R which escaped inactivation by the MAb held at the higher concentration. The concentration of the second MAb which permitted escape mutants to arise to the MAb kept at constant concentration varied non-reciprocally between 1 and 3 HIU/ml. It is significant that despite the dilution factor, these concentrations of the second MAb were themselves neutralizing under the conditions used, one HIU being defined as the concentration required to inhibit agglutination by 4HAU of virus which is equivalent to 1'6 × 108 particles (Taylor et al., 1987 , and data not shown).
These data were extended by assessing the ability of mixtures of three MAbs, specific for three different antigenic sites (A, B and D) to select escape mutants (Table 6b) . One MAb was held constant at 1000 HIU/ml while the others in the mixture were serially diluted in chequer-board fashion. Again escape mutants to the MAb held at high concentration emerged when the * Serial dilutions of MAb #2 in 1000 HIU/ml of MAb #1 (total of 1 ml) were incubated with 106 p.f.u, of A/FPV/Rostock/34 for 1 h at 25 °C. Thus the first set of 'pseudo-immune sera' in row 1 consisted of 1000 HIU of MAb HC2 containing 1000, 100, 10, 1, 0.1 or 0.01 HIU of MAb HC10. Repeat experiments were done with doubling dilutions of HC10. After incubation, virus-antibody mixtures were inoculated (100 [al) into embryonated chicken's eggs. Allantoic fluid was harvested from these after incubation for 48 h at 35 °C and assayed for progeny. The value shown for MAb #2 is the highest concentration at which escape mutants arose. One HIU is defined as the amount of antibody inhibiting agglutination of red blood cells by 4 HAU (1.6 x 108 virus particles: Taylor et al., 1987) .
?These results are a summary of chequer-board titrations. For example, the first 'pseudo-immune serum' giving escape mutants contained 1000 HIU of MAb HC2, 2 HIU of MAb HCI0 (left-hand panel) and 1 HIU of MAb HC61 (right-hand panel).
NA, Not applicable.
other two MAbs were present at lower, but still biologically significant, amounts. The escape mutants all belonged to Group I with > 99.7 % reduced reactivity against the selecting MAb (MAb #1), and unchanged activity against MAb #2 and MAb #3 (data not shown).
Discussion
The major conclusion of this paper is that 12% of antisera from mice in which a conventional secondary immune response had been generated selected neutralization escape mutants in a single passage. In this regard they were functionally indistinguishable from MAbs. Properties of escape mutants and the antisera with which they were selected are summarized in Table 4 . Although numbers of animals used were small, the ability to select escape mutants was found in three of the four strains of mouse tested and did not therefore appear to be a property of a particular genetic constitution. Escape mutants were generated with antisera from mice immunized with 10 or 100HAU, and after three administrations of immunogen. However, individual mouse responses were heterogeneous as 22% of antisera in Experiment 2/Protocol 2 were completely neutralizing. It would be interesting to know if the same type of escape mutant-selecting antisera resulted from infection with live virus, and how the immunization conditions affect the generation of such antisera. No adjuvant was used in this study. The proportion of escape mutants identified is a minimum figure since the remaining virus-positive samples in Experiments 1 and 2 (36/45; Fig. 1 ) could be escape mutants which reacted normally with our identifying MAbs or breakthrough wt virus. Three of these samples proved to consist of predominantly wt virus which concealed a minor proportion of mutants which escape our MAbs (Table 3) . However, because this was laborious, we tested only the 16 virus-positive samples from Experiment 2. Proportionately, we would expect to find around another five escape mutants from the 29 virus-positive samples in Experiment 1 which had not yielded escape mutants. Viruses which grew in the presence of antisera in the experiment shown in Fig. 2 were not investigated further.
The majority of our escape mutants showed little if any reactivity with the identifying MAb. With one exception they were all site A mutants, and the immunological evidence was confirmed by finding a predicted single amino acid substitution, Gly-144 ~ Glu, in site A. (Both A/FPV/R and A/FPV/D have Gly-144: Munk et al., 1992.) This suggests that the selecting antibody specificity in the antiserum was very similar to that of MAb HC2. We believe this result was not artefactual because (a) no escape mutant was isolated using sera from 65 non-immunized mice and 25 immunized mice with an undetectable HI titre; (b) one of the escape mutants contained a silent mutation not present in any of the other viruses and was unequivocally an independent isolation; and (c) in another study immune serum from a rabbit reproducibly selected escape mutants toHC10 (site B) (Taylor, 1986 ; N.J. Dimmock, unpublished data). A bias for site A of human strains of type A influenza virus was noted in the antibody response of both mice and rabbits, although without quantification (Webster & Laver, 1980; Laver et al., 1981) . The finding of an amino acid substitution in site A distinguishes our mutants from adsorptive non-antigenic mutants derived by others using mixtures of MAbs (Yewdell et al., 1986) and confirms our mutants as neutralizing antibody escape mutants. The minor changes in the Group II escape mutants are reminiscent of conformational rearrangements which are thought to accompany an amino acid substitution at another site (Brown et al., 1990) , and have been noted by others (Laver et al., 1981) . The ability of a Group I escape mutant to react with its selecting antiserum was reduced with respect to wt virus R. Lambkin and others from 50 to 75%, consistent with the escape mutation conferring upon them a selective advantage in vivo.
The emergence of escape mutants during a single selection passage with immune serum runs counter to conventional wisdom. Although it has been known for nearly half a century that escape mutants can be isolated using immune serum, they have emerged only after prolonged passage of viruses in vitro and usually with highly selected fractions of antiserum (influenza virus: Archetti & Horsfall, 1950; Isaacs, 1951; Laver & Webster, 1968; Fazekas de St Groth, 1978) or low concentrations of antiserum (foot-and-mouth disease virus: Rojas et al., 1992 , HIV-I: Reitz et al., 1988 McKeating et al., 1994) or in vivo where vaccination resulted in subprotective immunity (footand-mouth disease virus: Hyslop & Fagg, 1965 , hepatitis B virus: Carman et al., 1990 Harrison et al., 1991; Harrison & Zuckerman, 1992 , 1993 , treatment of persistent hepatitis B infection with MAb (McMahon et al., 1992) , or during persistent infection (HIV-1 : Albert et al., 1990; Arendrup et al., 1992 Arendrup et al., , 1993 Nara et al., 1990a, b; Tremblay & Wainberg, 1990; Montefiori et al., 1991; Watkins et al., 1993; Schreiber et al., 1994) . The favoured explanation of our data is that the mouse antisera capable of selecting escape mutants are functionally monoclonal; that is they contain a majority of neutralizing HA-specific, site A-specific antibodies whose epitope(s) overlap with that recognized by HC2. The latter is necessarily true since we and others have found that escape mutants can react normally with MAbs to the same site (other than the selecting MAb) which have non-overlapping paratopes. This explanation does not preclude the mouse from having any number of other antibody specificities providing that they are nonneutralizing, or other neutralizing HA-specific antibody specificities providing that these are at a sufficiently low level to permit escape mutants to arise, as seen with the 'pseudo-immune sera' examined in Table 6 . Although some animals exhibit a broad spectrum of antibody specificities to influenza virus (Laver & Webster, 1968; Staudt & Gerhard, 1983; Underwood, 1984) , a restricted antibody response to the HA has also been observed in man (Natali et al., 1981 ; Wang et al., 1986) and particularly in children (Haaheim, 1980) , and in mice. The latter was evidenced from study of the specificity (Smith et al., 1991) and V gene usage of HA-specific hybridomas (Clarke et al., 1990) , but neither observation was so extreme as to suggest the functional monoclonality that we have observed. Variation in the antibody response between individual mice may be the key to reconciling these apparently conflicting data.
The finding that our escape mutant-selecting immune sera have a HI/neutralizing antibody response functionally biased towards site A or indeed to a single epitope within site A suggests how rapid antigenic variation (antigenic drift) in type A influenza viruses could arise in the presence of serum antibody. However, there is an apparent discrepancy between the constitution of a mouse antiserum which selected an escape mutant and of the mixture of MAbs (to different antigenic sites) used to make the 'pseudo-immune sera' which also selected escape mutants. As judged by their reactivity with the escape mutants which they had selected, most mouse antisera contained 25 to 50 % of antibodies to other epitopes, while the 'pseudo-immune sera' could tolerate no more than 0.3% of antibody to another epitope. However, the latter represents the upper limit of antibodies to a second single epitope, and we have no information about the number of epitopes recognized by antiserum antibodies which recognize the escape mutant. In fact, a detailed comparison between the escape mutant-selecting antisera and the 'pseudo-immune sera' may not be justified, as this would be affected by factors such as the relative avidity of the constituent antibodies in a mouse antiserum, and the possible presence of a minor population of antibodies within the same antigenic site which were competitively inhibited from binding to virus by the selecting antibodies but were able to react with the escape mutant progeny. Again information is lacking.
This study also points to the need for monitoring neutralizing antibody responses against individual antigenic sites on the HA after human influenza vaccination, rather than merely monitoring the overall antibody titre, to ensure that a highly restricted immune response is not being stimulated and to avoid creating a situation whereby antigenic drift is being positively promulgated. While the antigenic complexity of proteins is not disputed, the data and conclusions presented above call into question their supposed immunogenic complexity.
